Prevalence of Human Papilloma Virus in Latvian Population in Year 2022

  • Beatrise Orlova (Speaker)
  • Marta Zariņa (Co-author)
  • Storoženko, J. (Co-author)
  • Skrode, E. (Co-author)
  • Marija Dončaka (Co-author)
  • Jana Osīte (Co-author)
  • Stella Lapiņa (Co-author)

Activity: Talk or presentation typesPoster presentation

Description

According to statistics, cervical cancer is one of the most commonly diagnosed types of cancer in the world and in Latvia as well. Human papilloma virus (HPV), which is the causative agent of cervical cancer, is one of the most frequent viral infections of the reproductive system and can be easily diagnosed. To reduce the incidence of cervical cancer, a nationwide screening program is of a great importance.. Data on the women who have responded to national screening programm in Latvia were gathered in SIA “Centrālā laboratorija” from the 1st of July, 2022 until the 1st of December, 2022. High-risk HPV type DNA testing was done by Cobas 6800, Roche. This test system detects and differentiates HPV type 16, 18 and makes a pull of other high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68). The amount of high-risk HPV DNA positive samples were estimated and compared to the prevalence of high-risk HPV types globally.. Overall 22 207 high-risk HPV DNA tests were performed. It was calculated that 11,1 % of the received samples were positive to at least one high risk-HPV type. These single-type HPV infections are more common than multiple-type HPV infections. Calculated co-infection rate was 0,9 % in the analyzed samples in a given period of time. The current global HPV prevalence is estimated to be 11,7%.. Testing data indicates that the prevalence of high-risk HPV types in Latvia is comparable with the global average. Testing with molecular diagnostics methods provides valuable statistical data that helps evaluate the prevalence of high-risk HPV in Latvian population. From the gathered data grounded conclusions can be drawn about necessary actions that need to be taken in order to reduce the rate of prevalence of cervical cancer in the upcoming years.
Period29 Mar 2023
Event titleRSU Research week 2023: Society. Health. Welfare
Event typeConference
Conference number9
OrganiserRīga Stradiņš University
LocationRiga, LatviaShow on map
Degree of RecognitionInternational